Kamada's Biologics License Application for IV-AAT to Treat Alpha-1 Antitrypsin Deficiency is Accepted for Review by the US Food and Drug Administration
NESS ZIONA, Israel--(BUSINESS WIRE)--Aug 4, 2009 - Kamada, a bio-pharmaceutical company engaged in the development, manufacturing and marketing of specialty...
New Drug Applications (FDA) · More like this

Kamada Submits U.S. Biologics License Application for the First Liquid, Ready to Use AAT for the Treatment of Alpha-1 Antitrypsin Deficiency
...License Application ('BLA') to the U.S. Food and Drug Administration ('FDA') for its lead clinical candidate, intravenous alpha-1 antitrypsin ('AAT-IV'), for the treatment of Alpha-1 Antitrypsin Deficiency. David Tsur, Chief Executive Officer of Kamada, said, 'The submission of our AAT-IV BLA is...
New Drug Applications (FDA) · More like this

Having trouble finding what you want?

• Try browsing our A-Z List of Drug Names or our Medical Encyclopedia.
• Try posting your query on the Drugs.com Community Discussion Boards
• Drug Interactions Checker provides detailed information on drug-drug and drug-food interactions.
• Pill Identifier will help you identify an unknown pill by imprint code or shape/color.
• Image Search is helpful if you want to know what a certain pill looks like.
• News, FDA Approvals or In The Pipeline may help if the drug you are looking for is a new drug.